Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citationSingle-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 Diabetes
Hering, B. J. (2005) · JAMA · doi:10.1001/jama.293.7.830 · Cited by 592 · cited 1×
“Other Study Treatments Induction immunosuppression consisted of rabbit anti–thymocyte globulin and etanercept (13) for the first transplant, with basiliximab replacing rabbit anti–thymocyte globulin at subsequent transplants.”
BackgroundSelf-citationIncreased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539 · cited 1×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications
Frier, B. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.170 · Cited by 481 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundRestoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes.
Cranston, I., Lomas, J., Amiel, S. A., Maran, A., & Macdonald, I. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91336-6 · Cited by 430
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
Fanelli, C. G., Epifano, L., Rambotti, A. M., Pampanelli, S., Di Vincenzo, A., Modarelli, F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993) · Diabetes · doi:10.2337/diab.42.11.1683 · Cited by 398
Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes
Geddes, J., Schopman, J. E., Zammitt, N. N., & Frier, B. M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02413.x · Cited by 387 · cited 1×
“T1D (3,4), confers a threefold to sixfold”
Ryan, E. A., Shandro, T., Green, K., Paty, B. W., Senior, P. A., Bigam, D., Shapiro, A. M. J., & Vantyghem, M.-C. (2004) · Diabetes · doi:10.2337/diabetes.53.4.955 · Cited by 343 · cited 2×
“Other efficacy outcomes included glycemic lability index (LI) (19), hypoglycemia score (19), and 72-h glucose profiles by use of a CGMS (Medtronic”
BackgroundMethodSelf-citationWeinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338
Self-citationReversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.
Dagogo-Jack, S., Rattarasarn, C., & Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.12.1426 · Cited by 328
Hopkins, D., Lawrence, I., Mansell, P., Thompson, G., Amiel, S., Campbell, M., & Heller, S. (2012) · Diabetes Care · doi:10.2337/dc11-1579 · Cited by 265 · cited 3×
“T1D (3,4), confers a threefold to sixfold”
BackgroundThe current state of pancreas transplantation
Gruessner, R. W. G., & Gruessner, A. C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.138 · Cited by 256
Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233 · cited 5×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundInfluentialSelf-citationHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214
Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S., & Amiel, S. A. (2015) · Diabetes Care · doi:10.2337/dc15-0102 · Cited by 154 · cited 4×
“Currently, the majority of patients presenting with problematic hypoglycemia are expected to experience resolution of severe hypoglycemia with optimal medical therapy that includes access to these interventions in a stepped-care approach (7,8,10).”
BackgroundInfluentialKendall, D. M., Rooney, D. P., Smets, Y. F. C., Salazar Bolding, L., & Robertson, R. P. (1997) · Diabetes · doi:10.2337/diab.46.2.249 · Cited by 134
Diem, P., Redmon, J. B., Abid, M., Moran, A., Sutherland, D. E., Halter, J. B., & Robertson, R. P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114936 · Cited by 134 · cited 1×
“taneous kidney transplant (26), is the only other intervention capable of achieving similar results (27,28), but is uncommonly used in nonuremic T1D patients (26).”
BackgroundMulticenter Australian Trial of Islet Transplantation: Improving Accessibility and Outcomes
O’Connell, P. J., Holmes-Walker, D. J., Goodman, D., Hawthorne, W. J., Loudovaris, T., Gunton, J. E., Thomas, H. E., Grey, S. T., Drogemuller, C. J., Ward, G. M., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12250 · Cited by 114
A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study
de Zoysa, N., Rogers, H., Stadler, M., Gianfrancesco, C., Beveridge, S., Britneff, E., Choudhary, P., Elliott, J., Heller, S., & Amiel, S. A. (2014) · Diabetes Care · doi:10.2337/dc13-1245 · Cited by 103 · cited 2×
“and/or behavioral therapies aimed at hypoglycemia awareness restoration (4,36,37) improve the awareness of hypoglycemia, hormonal counter-regulation”
BackgroundReport from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
Bartlett, S. T., Markmann, J. F., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D., Kay, T. W. H., Bromberg, J., Odorico, J. S., Weir, G. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001055 · Cited by 75
Self-citationBrooks, A. M., Walker, N., Aldibbiat, A., Hughes, S., Jones, G., de Havilland, J., Choudhary, P., Huang, G. C., Parrott, N., McGowan, N. W. A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12469 · Cited by 60
Naziruddin, B., Wease, S., Stablein, D., Barton, F. B., Berney, T., Rickels, M. R., & Alejandro, R. (2012) · Cell Transplantation · doi:10.3727/096368911x612468 · Cited by 52 · cited 1×
“DSAs developed in few subjects (2 of 48 subjects [4%]) compared with other islet and organ transplant studies (24,25).”
ResultSelf-citationBeck, R. W., Raghinaru, D., Wadwa, R. P., Chase, H. P., Maahs, D. M., Buckingham, B. A., & for the In Home Closed Loop Study Group (2014) · Diabetes Care · doi:10.2337/dc13-2775 · Cited by 45 · cited 1×
“Emerging diabetes technologies such as next-generation insulin pumps with predictive lowglucose management technology (38) and closed-loop pumps with glucoseresponsive insulin or insulin and glucagon delivery (39) have not yet been tested in patients with T1D and problematic hypoglycemia; further testing is needed to…”
Background2012 annual literature review of donor-specific HLA antibodies after organ transplantation.
Kaneku, H. (2011) · PubMed · Cited by 21
Byrne, M., Hopkins, D., Littlejohn, W., Beckford, R., Srinivasan, P., Heaton, N., Amiel, S., & Choudhary, P. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1394455 · Cited by 20 · cited 5×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundInfluential
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
“For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (98,99).”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Clinical pancreatic islet transplantation
Shapiro, A. M. J., Pokrywczynska, M., & Ricordi, C. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.178 · Cited by 747
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.